Since the beginning of this year we have created four webinars to present our BIOMIMESYS® technology and practical uses. We have chosen to focus on the scientific side of our innovation by presenting results in drug discovery or dermocosmetology domains. Theses four webinars are available on our support page (with many Read more…
Pharmaceutical industry is facing a very high failure rate in drug discovery, with 90% of failure in clinical trials. This is particularly true for central nervous system applications, with a rate of 30% safety failure in clinical trials, compared to 7% in preclinical trials (Cook et al. 2014). This reveals Read more…
The annual congress of the SCMC (Societé Cerveau et Maldies Cérébraux Vasculaires – Brain and cerebrovascular diseases Society) will take place this Friday, may 28 2021 (virtual congress). On this occasion, our PhD student Véronique De Conto will present her PhD works, which concern the development of new cerebral in Read more…
Ask for high quality link by putting your email below There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study Read more…
The international NeuroFrance congress will take place May, 19, 20 and 21th 2021 (virtual meeting). On this occasion, our PhD student Véronique De Conto will present these works in a poster about the importance of matricial and cellular microenvironment for drug discovery in Parkinson’s disease (summary below). Feel free to Read more…
When Tuesday, June 1, 2021 – 1PM (CET) / 8PM (CST) / 9PM (JST) / 7AM (EST) Thursday, June 3, 2021 – 9AM (CET) / 4PM (CST) / 5PM (JST) / 3AM (EST) Where Online, using zoom.us and live on Youtube What Pharmaceutical industry is facing a very high failure rate in Read more…
Soria et al. has published this year an interesting study about the modification leading by synucleopathy on the nanoscale organization and diffusivity of the extracellular space, through hyaluronan remodeling. Indeed the extracellular space (ECS), composed by the interstitial fluid and the extracellular matrix (ECM), plays several roles in health and Read more…
Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi bodies. This neuronal loss leads to a decrease in the neurotransmitter dopamine that cause mainly Read more…
Vaihere Cheung obtained her technology A-level (STL) in 2018 at La Mennais, in French Polynesia. Then she came to metropolitan France to reach a technician diploma in Biological engineering, specialized in biological and biochemical analysis, at the University of Lyon. During her studies, Vaihere did an internship in HCS Pharma Read more…
The human brain contains approximately 86 billon neurons of different types, distributed and organized in different areas ; their functions vary according to the neuron type and its localization within the brain. However, the neuronal function also depends on its microenvironment, which is composed of the extracellular matrix (ECM), and Read more…
Elisa Moya started her bachelor’s degree in 2013, in Biological Sciences, at the University of Granada, Spain. During her career period, in 2015, she studied one year in Portugal (Erasmus+). Moreover, in the summer 2016, she participated during 3 months in a research project dealing with Alzheimer’s disease in Newcastle Read more…
The extracellular matrix (ECM) is composed of macromolecules surrounding the cells. They interact with each other and with the cells, cross-link and polymerize, ensuring the maintenance and the function of organs. The primary role of ECM is to support the cells by providing adhesion support, but its role goes beyond: Read more…
James W. Fawcett published the review « The extracellular matrix in plasticity and regeneration after CNS injury and neurodegenerative disease » in 2015, highlighting the key role of the chondroitin sulfate proteoglycans (CSPGs) of the extracellular matrix (ECM) in brain plasticity. CSPGs are present in the brain extracellular matrix and Read more…
The annual congress of Biology and Health PhD students from Lille (André Verbert day) took place at the Faculty of Medicine Thursday, September 10th. During this day, PhD students, in third year of thesis, had to present their works by talks, flash-talks or posters. Our PhD student Véronique De Conto Read more…
The founding congress of the french STCM (Société de Toxicologie Cellulaire et Moléculaire) will take place in Paris at the end of this week (13th-14th June, 2019). The theme of this meeting will be “Toxicology towards the 3rd dimension“. We are looking forward to attending this congress, and to becoming Read more…
The annual SCMC congress (Société Cerveau et Maladies Cérébrovasculaires – Brain and Cerebrovascular diseases Society) took place in Lille last week, in the Faculty of Medecine. The congress was organized in three sessions. The first session was about cerebrovascular development and maturation. The conferences began with a lecture about blood-brain Read more…
Next week HCS Pharma will be present both at Forum Labo Paris (26th-28th March ) and at SCMC congress in Lille (28-29th March)! In Forum Labo we will have our own stand in the Lab’StartUp Village (stand G11), thanks to the organizers for selecting BIOMIMESYS® Brain for the fair! We Read more…
HCS Pharma is one of the winner of the Lab’StartUp village, organized by Forum Labo! As such, we have won a stand in the heart of the forum (March 26-28, 2019)… Thanks a lot to the committee for evaluating our application to this prize, and for selecting our new product Read more…
We are developing a new BIOMIMESYS® hydroscaffold for neuronal cells. First results are very promising because neurons grow and form neurites. Moreover cells lived longer than in monolayer culture. We are currently finalizing this new hydroscaffold to find the best conditions of 3D neuron culture, but BIOMIMESYS® Brain will be soon Read more…
Abstract Bevacizumab is a humanized monoclonal antibody directed against the pro-angiogenic factor vascular and endothelial growth factor-A (VEGF-A) used in the treatment of glioblastomas. Although most patients respond initially to this treatment, studies have shown that glioblastomas eventually recur. Several non-mutually exclusive theories based on the anti-angiogenic effect of bevacizumab Read more…
